Literature DB >> 20007265

Fine mapping of pre-S sequence requirements for hepatitis B virus large envelope protein-mediated receptor interaction.

Andreas Schulze1, Alexa Schieck, Yi Ni, Walter Mier, Stephan Urban.   

Abstract

Previous studies showed that the N-terminal 75 amino acids of the pre-S1 domain of the hepatitis B virus (HBV) L protein are essential for HBV and hepatitis delta virus (HDV) infectivity. Consistently, synthetic lipopeptides encompassing this sequence or only parts of it efficiently block HBV and HDV infection, presumably through specific interference with a cellular receptor. Crucial for both virus infectivity and the inhibitory activity of the peptides are N-terminal myristoylation and a highly conserved motif within the N-terminal 48 amino acids. To refine the sequence requirements, we synthesized a series of HBV pre-S1 peptides containing deletions, point mutations, d-amino acid exchanges, or genotype-specific sequence permutations. Using the HepaRG cell line and a genotype D-derived virus, we determined the specific inhibitory activities of the peptides and found that (i) lipopeptides with an artificial consensus sequence inhibit HBV genotype D infection more potently than the corresponding genotype D peptides; (ii) point mutations, d-amino acid exchanges, or deletions introduced into the highly conserved part of the pre-S1 domain result in an almost complete loss of activity; and (iii) the flanking sequences comprising amino acids 2 to 8, 16 to 20, and, to a less pronounced extent, 34 to 48 gradually increase the inhibitory activity, while amino acids 21 to 33 behave indifferently. Taken together, our data suggest that HBV pre-S1-mediated receptor interference and, thus, HBV receptor recognition form a highly specific process. It requires an N-terminal acyl moiety and a highly conserved sequence that is present in primate but not rodent or avian hepadnaviruses, indicating different entry pathways for the different family members.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20007265      PMCID: PMC2812397          DOI: 10.1128/JVI.01902-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  36 in total

1.  Structural and functional characterization of a monoclonal antibody specific for the preS1 region of hepatitis B virus.

Authors:  J C Pizarro; B Vulliez-le Normand; M M Riottot; A Budkowska; G A Bentley
Journal:  FEBS Lett       Date:  2001-12-14       Impact factor: 4.124

Review 2.  Hepatitis B virus infection--natural history and clinical consequences.

Authors:  Don Ganem; Alfred M Prince
Journal:  N Engl J Med       Date:  2004-03-11       Impact factor: 91.245

Review 3.  Hepatitis B virus biology.

Authors:  C Seeger; W S Mason
Journal:  Microbiol Mol Biol Rev       Date:  2000-03       Impact factor: 11.056

4.  A short N-proximal region in the large envelope protein harbors a determinant that contributes to the species specificity of human hepatitis B virus.

Authors:  P Chouteau; J Le Seyec; I Cannie; M Nassal; C Guguen-Guillouzo; P Gripon
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

5.  Inhibition of duck hepatitis B virus infection by a myristoylated pre-S peptide of the large viral surface protein.

Authors:  Stephan Urban; Philippe Gripon
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

6.  Infection of a human hepatoma cell line by hepatitis B virus.

Authors:  Philippe Gripon; Sylvie Rumin; Stephan Urban; Jacques Le Seyec; Denise Glaise; Isabelle Cannie; Claire Guyomard; Josette Lucas; Christian Trepo; Christiane Guguen-Guillouzo
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-13       Impact factor: 11.205

7.  Amino acid residue penultimate to the amino-terminal gly residue strongly affects two cotranslational protein modifications, N-myristoylation and N-acetylation.

Authors:  T Utsumi; M Sato; K Nakano; D Takemura; H Iwata; R Ishisaka
Journal:  J Biol Chem       Date:  2000-12-20       Impact factor: 5.157

8.  Pre-s1 antigen-dependent infection of Tupaia hepatocyte cultures with human hepatitis B virus.

Authors:  Dieter Glebe; Mehriar Aliakbari; Peter Krass; Eva V Knoop; Klaus P Valerius; Wolfram H Gerlich
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

9.  A function essential to viral entry underlies the hepatitis B virus "a" determinant.

Authors:  Jessica Salisse; Camille Sureau
Journal:  J Virol       Date:  2009-07-01       Impact factor: 5.103

10.  Vertical-scanning mutagenesis of amino acids in a model N-myristoylation motif reveals the major amino-terminal sequence requirements for protein N-myristoylation.

Authors:  Toshihiko Utsumi; Kengo Nakano; Takeshi Funakoshi; Yoshiyuki Kayano; Sayaka Nakao; Nagisa Sakurai; Hiroyuki Iwata; Rumi Ishisaka
Journal:  Eur J Biochem       Date:  2004-02
View more
  81 in total

1.  Robust Human and Murine Hepatocyte Culture Models of Hepatitis B Virus Infection and Replication.

Authors:  Luhua Qiao; Jianhua Sui; Guangxiang Luo
Journal:  J Virol       Date:  2018-11-12       Impact factor: 5.103

2.  How the key finds its door - identification of HBV receptor.

Authors:  Yun Wang; Xinwen Chen
Journal:  Virol Sin       Date:  2013-01-16       Impact factor: 4.327

Review 3.  Treatment of hepatitis B virus: an update.

Authors:  Haley Ward; Lydia Tang; Bhawna Poonia; Shyam Kottilil
Journal:  Future Microbiol       Date:  2016-11-18       Impact factor: 3.165

4.  Hepatitis B Virus DNA Integration Occurs Early in the Viral Life Cycle in an In Vitro Infection Model via Sodium Taurocholate Cotransporting Polypeptide-Dependent Uptake of Enveloped Virus Particles.

Authors:  Thomas Tu; Magdalena A Budzinska; Florian W R Vondran; Nicholas A Shackel; Stephan Urban
Journal:  J Virol       Date:  2018-05-14       Impact factor: 5.103

Review 5.  Bile Acid Uptake Transporters as Targets for Therapy.

Authors:  Davor Slijepcevic; Stan F J van de Graaf
Journal:  Dig Dis       Date:  2017-03-01       Impact factor: 2.404

6.  Antibody-mediated immunotherapy against chronic hepatitis B virus infection.

Authors:  Ying Gao; Tian-Ying Zhang; Quan Yuan; Ning-Shao Xia
Journal:  Hum Vaccin Immunother       Date:  2017-05-19       Impact factor: 3.452

Review 7.  Mechanism of Hepatitis B Virus Persistence in Hepatocytes and Its Carcinogenic Potential.

Authors:  Maura Dandri; Joerg Petersen
Journal:  Clin Infect Dis       Date:  2016-06-01       Impact factor: 9.079

8.  In silico analysis and experimental validation of azelastine hydrochloride (N4) targeting sodium taurocholate co-transporting polypeptide (NTCP) in HBV therapy.

Authors:  L-L Fu; J Liu; Y Chen; F-T Wang; X Wen; H-Q Liu; M-Y Wang; L Ouyang; J Huang; J-K Bao; Y-Q Wei
Journal:  Cell Prolif       Date:  2014-06-26       Impact factor: 6.831

9.  Entry of hepatitis B virus into immortalized human primary hepatocytes by clathrin-dependent endocytosis.

Authors:  Hsiu-Chen Huang; Chun-Chi Chen; Wen-Cheng Chang; Mi-Hua Tao; Cheng Huang
Journal:  J Virol       Date:  2012-06-27       Impact factor: 5.103

10.  Sodium taurocholate cotransporting polypeptide mediates woolly monkey hepatitis B virus infection of Tupaia hepatocytes.

Authors:  Guocai Zhong; Huan Yan; Haimin Wang; Wenhui He; Zhiyi Jing; Yonghe Qi; Liran Fu; Zhenchao Gao; Yi Huang; Guangwei Xu; Xiaofeng Feng; Jianhua Sui; Wenhui Li
Journal:  J Virol       Date:  2013-04-17       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.